Patient #:	1	2	3	4
Current Age	50	54	48	38
Sex	M	M	M	M
Race	White	White	White	White
Ethnicity	Hispanic	Hispanic	Non-Hispanic	Hispanic
MSM Status	Yes	Yes	Yes	Yes
Years with HIV	0.5	7.5	1.8	7.9
Age at Dx of MCD	50	47	46	35
HHV-8 Status at Time of MCD Dx	Positive	Positive	Positive	Positive
Comorbidities	Kaposi Sarcoma Hx of Salmonella Sepsis	Hepatitis C Virus Primary Effusion Lymphoma Squamous Intraepithelial Rectal lesion (p16+) Herpes Zoster Virus Hx of Secondary Sphilis HPV Rectal Condyloma Hx of Gonorrhea Hx of Chlamydia	IRIS Hx of H. pylori Gastritis Hx of CMV Colitis Hx of Chlamydial Lymphogranuloma Hx of Syphilis Hx of Chlamydia	Anal Papilloma Thrombocytopenia Hyperlipidemia HPV Oral Candidiasis HHV-6
HIV Treatment(s)	1. bictegravir, emtricitabine, & tenofovir (current)	Hx of atazanavir, ritonavir, emtricitabine, & tenofovir Hx of atazanavir, cobicistat, emtricitabine, & tenofovir Hx of elvitegravir, cobicistat, emtricitabine, & tenofovir bictegravir, emtricitabine, & tenofovir (current)	Hx of emtricitabine, tenofovir, & dolutegravir Hx of bictegravir, emtricitabine, & tenofovir Currently untreated	Hx of raltegravir, emtricitabine, & tenofovir Hx of dolutegravir, abacavir, & lamivudine Hx of darunavir, ritonavir, dolutegravir, & rilpivirine Hx of darunavir, ritonavir, dolutegrarvir, emtricitabine, & tenofovir dolutegrair, emtricitabine, & tenofovir (current)
Last CD4+ count before MCD Dx (cells/mm3)	49	85	451	102

Table 1: Demographics and medical history of patients diagnosed with MCD

Patient	MCD Treatment	Length of Remission
1	rituximab & doxorubicin	5 months
2	R-EPOCH x6 (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)	7 years & 5 months (89 months)
3	Chemo declined	N/A
4	rituximab x10, gamma globulin x2	2 years & 10 months (34 months)

Studies of HIV/HHV-8+ patients with MCD treated with rituximab
Study	n of patients	Associated treatment	Survival (mos)
Corbellino, et al. [18]	1	None	14+
Marcelin, et al. [20]	5	None	4+, 6+, 14+, 1, 1
Newsom-Davis, et al. [22]	1	None	4+
Neuville, et al. [21]	2	etoposide	22+, 32+
Gérard, et al. [17]	24	None	12+ (n = 22) 1 (n = 1) 4 (n = 1)